Stockreport

EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) [Yahoo! Finance]

Genmab A/S - American Depositary Shares  (GMAB) 
PDF Wainwright cut its price target for Genmab A/S (NASDAQ:GMAB) to $39 from $41, retaining a Buy rating on the company's shares. The change comes after Genmab and partner A [Read more]